The hematopoietic system undergoes a qualitative change during the embryogenesis of most vertebrates. It is designated as the shift of primitive to definitive hematopoiesis and suitable microenvironment must be established to support this shift. While studying the role of platelet derived growth factor receptor a (PDGFR a) in embryonic hematopoiesis, we found that it was expressed in a stromal cell component of liver, a major site of this shift, but not in the yolk sac, the site of primitive hematopoiesis. Thus, we considered that development of PDGFRa positive stromal cells is an essential requirement for this shift. Without PDFGRa positive cell component, erythropoiesis was suppressed in the culture of fetal liver. Moreover, injection of an antagonistic anti-PDGFRa monoclonal antibody during embryogenesis suppressed the production of definitive erythrocytes. These indicated that PDGF exerts its effect on a subset of stromal components to prepare a microenvironment that can support the definitive erythropoiesis.
Among about 200 cell types constituting the mammalian body, hematopoietic cells are generated most rapidly. In mice, fully mature erythrocytes are detectable at 8 days of gestation, when most other cell lineages still remain at intermediate stages. However, this early wave of hematopoiesis should undergo a qualitative change to establish the hematopoietic system that continues throughout life. This shift of primitive to definitive hematopoiesis is considered to be a cell autonomous process accompanying changes in the repertoire of key transcriptional regulator, such as the c-myb (1) and AML1/RUNX1 (2). However, a null mutation in erythropoietin (Epo) receptor gene (3, 4) and Epo gene (3) results in the failure of the production of adult type mature erythrocytes, indicating that the stromal cell components producing some factors to support hematopoiesis also play an essential role in the shift from primitive to definitive erythropoiesis. Although it has been widely believed that Epo is produced from the fetal liver and gradually production site of Epo shifts to the kidney, recent analysis revealed that Epo production is observed equally in the kidney as well as the fetal liver during early embryogenesis when fetal hematopoiesis starts (5) . Therefore, erythropoiesis might be affected by Epo circulating in peripheral blood as well as it produced in the fetal liver. Most importantly, erythropoiesis cannot be regulated only by a circulating Epo, but also by matrix proteins and another cytokine such as c-kit ligand, stem cell factor (SCF) (6) that are produced from stromal cell components in hematopoietic tissues.
A recent study of mice bearing a null mutation in platelet derived growth factor (PDGF)-B (7) or its receptor (PDGFR)b (8) showed that most mutant embryos develop fatal hemorrhage before birth and this hemorrhage leads to erythroblastosis, macrocytic anemia and thrombocytepenia. Then anemia looked in those mutants was indicated as the secondary effect of hemorrhage. It was shown, however, anemia occurs in mutants before any obvious sign of bleeding. Then PDGF-B and PDGFRb may be involved in the production of erythrocyte. Consistent with these functional studies, several investigators have detected PDGFRa in embryonic erythroblasts by in situ hybridization (9) or immunohistochemistry (10) . Moreover, since c-Kit that belongs to the same family of receptor tyrosine kinases, are involved in the proliferation of hematopoietic stem cells (11) , and differentiation of erythroblast (6) . PDGFRa, when expressed in the hematopoietic stem cell, should be able to take over the same function. Although mice carrying a targeted null mutation of PDGFRa gene were reported to show early embryonic lethality, hematological analysis has not been performed (12) .
Previously, we established a monoclonal antibody (mAb)PDGF signal in the embryonic hematopoiesis. In this study, we examined which cells in the hematopoietic tissues express PDGFRa, and how they are involved in hematopoiesis. We showed that PDGFRa is not expressed in hematopoietic cells, whereas it is in the stromal/fibroblastic cells of embryonic hematopoietic tissues, and that PDGFRa plays a role for the shift from primitive to definitive erythropoiesis. This indicates that the generation and stimulation of PDGFRa + stromal cell component play an essential role in establishing the microenvironment that supports the shift of erythropoiesis from primitive to the adult type.
MATERIALS AND METHODS
Animals-C57BL/6 mice and pregnant mice were purchased from Japan SLC Inc. (Shizuoka, Japan). The noon when a vaginal plug was detected was designated as embryonic day 0.5 of gestation (E0.5).
Immunohistochemistry-Tissue fixation procedures were basically as described (16) . Fixed specimens were embedded in polyester wax and sectioned at 8 mm as described (17) . Immunostaining proceeded as described (15) . In brief, sections were incubated with anti-c-Kit mAb, ACK2 (18, 19) , anti-PDGFRa mAb, APA5 (13) (14) (15) , anti-flk1 mAb, AVAS12 (20) , or anti-embryonic (21) or -adult (Cappel, Durham, NC) hemoglobin polyclonal antibody. Sections were incubated with a peroxidase conjugated secondary antibody, anti-rat-IgG antibody (Biosource, Camarillo, CA) for ACK2, APA5 and AVAS12, or anti-rabbit-IgG (Biosource) for both of anti-hemoglobin antibody and then color reaction was performed with diaminobenzidine (Dojin Chem., Kumamoto, Japan).
Procedure of whole-mount immunohistostaining was the same as described (15) . In brief, the primary antibody was visualized by incubating 1 mg/ml peroxidase-conjugated anti-rat-Ig antibody (Biosource) overnight at 4 C. After extensive washing, the specimens were soaked in PBS containing 0.1% Triton X-100, 0.05% NiCl 2 and 250 mg/ml diaminobenzidine (Dojin Chem.) for 10-30 minutes, then hydrogen peroxide was added to a final concentration of 0.01%. The enzymatic reaction proceeded until the desired color-intensity was reached, then the specimens were rinsed 3-4 times in PBST.
Cell Preparation and Flow Cytometry-The fetal liver at E12.5 was dissociated by Dispase II (Boehringer Mannheim, Mannheim, Germany) and drawn through a 23G needle. Fetal liver cells (5 · 10 5 ) prepared from embryos (16) were suspended in 50 ml of 5% FCS containing PBS. The cell-staining procedure for the flow cytometry was as described previously (17) . The monoclonal antibodies (mAbs) used in immunofluorescence staining were antib1 integrin antibody, anti-lineage (ter119, Gr-1, Mac-1, B220, CD4, CD8) antibodies (all purchased from Pharmingen), anti-PDGFRa antibody (APA5) and anti-c-Kit antibody (ACK2). All mAbs were purified and conjugated with either FITC, PE (phycoerythrin), or biotin. Biotinylated antibodies were visualized with PE-conjugated streptavidin or APC-conjugated streptavidin (Pharmingen). Cells were incubated for 5 min on ice with 1:100 dilution of CD16/32 (FcgIII/II Receptor, (1:100) [Fcblock TM ]; Pharmingen) prior to staining with primary antibody. The stained cells were analyzed by FACS calibur (Becton Dickinson, San Jose, CA) and sorted by EPICS Flow cytometer (ALTRA: Beckman Coulter, San Jose, CA). Sorted TER119 positive erythroid cells from APA5 or control antibody injected fetal liver were attached on glass and stained with anti-embryonic hemoglobin antibody as described previously (17) .
Cell Culture and CFU-c Analysis-Single cell suspension from E12.5 fetal liver was stained with anti-PDGFRa antibody, and then PDGFRa positive fraction was eliminated by cell sorting. 1 · 10 5 sorted fetal liver cells not containing PDGFRa positive cells and fetal liver cells containing both PDGFRa negative and positive cells once sorted for making even condition in cell preparation were cultured on 12 well fibronectin coated dishes (Becton Dickinson, Bedford, MA) in RPMI (Sigma, St. Louis, MO) containing 10% FCS in the presence or absence of 10 ng/ml PDGF (Peprotech, London, UK) at 37 C in a 5% CO 2 incubator for 7 days. For the analysis of Epo induction from fetal liver cells, fetal liver cells were harvested after 24 h and RNA was extracted. After culturing, all cells were harvested and subjected to the colony formation unit in culture (CFU-c) assay as described previously (22) . Colony containing only erythrocyte was counted as CFU-E after 4 days of culturing. The total number of hematopoietic colonies [i.e., CFUgranulocyte (G), macrophage (M) and granulocyte/macrophage (GM)] was counted as another CFU-c after 7 days of culturing.
RT-PCR Analysis-The RNeasy Mini kit (Qiagen GmbH, Hilden, Germany) was used for isolation of total RNA from cells from fetal liver. Total RNA was reverse transcribed using the RT for PCR kit (Clontech, Palo Alto, CA). The cDNA was amplified using Advantage Polymerase Mix (Clontech) in a GeneAmp PCR system model 9700 (Perkin-Elmer Inc., Norwalk, CT) by 30 to 35 cycles. The sequences of the gene-specific primers for RT-PCR were as follows:
0 -b-actin (TCTTCATGGTGCTAG-GAGCCA). Each cycle consisted of denaturation at 94 C for 30 s, and annealing/extension at 70 C for 4 min. Maternal Injection of Monoclonal Antibodies-Pregnant mice were given an intravenous injection of anti-PDGFRa mAb, APA5 (2 mg) daily from E9.5 to E13.5. Rat antimurine IL-7 receptor mAb, A7R34 (23) was used as an isotype-matched control and injected as described above. The mice injected with antibodies were sacrificed at E15.5 by cervical dislocation and embryos were fixed with cold 4% paraformaldehyde containing PBS (pH 7.4). Fixed specimens were embedded into polyester wax and sectioned at 5 mm.
RESULTS

Expression of PDGFRa in Fetal Hematopoietic Tissues-
To gain insight on the expression of PDGFRa in the fetal tissues, embryos were whole mount immunohistostained by the anti-PDGFRa mAb, APA5, with particular focus in the yolk sac where hematopoiesis has been demonstrated to take place. Because previous studies (24) (25) (26) (27) suggest that c-Kit is expressed and functioning in the fetal hematopoietic stem cells, embryos were also stained with the anti-c-Kit mAb, ACK2.
Although it was suggested that hematopoietic cells in the blood island express PDGFRa, we could not detect PDGFRa expression in any cells in the yolk sac (Fig. 1A ) in embryonic day (E) 9.5. In contrast, blood islands in the yolk sac were stained as scattered dots by c-Kit + cells (Fig.  1B) . In this stage, yolk sac was organized by the nest of Flk-1 positive endothelial cells (Fig. 1C) .
To further analyze the cells expressing PDGFRa in the hematopoietic organ, we immunostained the sections of E12.5 liver. PDGFRa staining was most intense in the mesenchymal cells surrounding the fetal liver. In addition, we also detected PDGFRa + cells scattered in the parenchyma of developing fetal liver (Fig. 1D) . These are bipolar fibroblastic cells and different from the round cells stained by anti-c-Kit mAb, ACK2 (Fig. 1E) . Moreover, PDGFRastaining remarkably differed from that by anti-Flk1 mAb that marks vascular endothelium (Fig. 1F) .
To confirm that no hematopoietic cell lineages in the embryonic tissues express PDGFRa, we performed flowcytometric analysis of fetal liver cells from E12.5 embryos using a number of hematopoietic cell markers. As shown in Fig. 2 observe the expression PDGFRa, whereas almost all PDGFRa cells express b1 integrin, one of the mesenchymal marker. Moreover, we could not detect PDGFRa cells of hematopoietic lineage in the yolk sac (data not shown). These results indicated that PDGFRa is not expressed in any embryonic hematopoietic lineage cells, whereas it was expressed in the stromal cell component.
Anti-PDGFRa Antibody Suppressed the Production of Adult type Erythrocytes in Embryos-To investigate the role of PDGFRa in hematopoiesis, we used anti-PDGFRa antibody that blocks the binding of PDGFRa to both PDGF-A and PDGF-B (13, 14) and observed fetal liver hematopoiesis. Pregnant mice were given an intravenous injection of 2 mg anti-PDGFRa antibody every day from E9.5 to E13.5, and the embryos were examined on E15.5. As shown in Fig. 3 , the numbers of mature enucleated erythrocytes in the fetal liver treated with anti-PDGFRa antibody (Fig. 3B) were small compared with those treated with control Ig, anti-IL7 receptor (R) mAb (Fig. 3A) and there were many nucleated erythrocytes (arrow heads) in anti-PDGFRa antibody treated fetal liver (Fig. 3B) . When hemoglobin staining was performed, many erythrocytes in the fetal liver treated with anti-PDGFRa antibody were of the fetal type stained with anti-embryonic and anti-adult type hemoglobin antibody (Fig. 3, D and F) . We sorted TER119 positive erythroid cells from the fetal liver and counted the number of embryonic hemoglobin positive fetal type erythroid cells among total erythroid cells. Result revealed that 37 -7% (n = 5) among total TER119 positive erythroid cells was of fetal type. On the other hand, most erythrocytes in the embryo that had been given control anti-IL7R mAb expressed adult type hemoglobin but not fetal hemoglobin (Fig. 3, C and E). As described above, we observed the ratio of fetal type erythroid cells among total TER119 positive erythroid cells obtained by cell sorting. Result revealed that 5 -1% (n = 5) was of fetal type. No substantial defect was detected in cells of other lineages confirmed by May-GruenwaldGiemsa staining and flow cytometric analysis (data not shown).
This result suggested that the PDGFRa signal is involved in the generation of adult type erythrocytes.
PDFGRa Positive Cells Are the Source of Erythropoietin in the Fetal Liver and Support Definitive ErythropoiesisEpo and Epo receptor-deficient mice die in utero due to a marked reduction in the number of committed fetal liver derived erythroid progenitors, resulted in lack of enucleated mature erythrocyte development (3, 4) . The fetal liver acts as the primary site of synthesis of Epo (5, 28) . Therefore, we observed the expression of Epo in PDFGRa positive cells from the fetal liver. As shown in Fig. 4 , Epo expression was observed in PDGFRa positive cells but not in PDGFRa negative cells in the fetal liver. On the other hand, in case of expression of other growth factors such as thrombopoietin (TPO) and stem cell factor (SCF), which are involved in generation of hematopoietic progenitors, PDGFRa negative fraction expressed both of TPO and SCF but PDGFRa positive fraction did not express SCF. These indicated that PDGFRa positive cells in the fetal liver can support definitive erythropoiesis by producing Epo, and that blockade of PDGFRa signaling by antiPDGFRa antibody injection affected the generation of enucleated mature erythrocyte. However, it is unclear whether total administration of PDGFRa antibody directly affects the PDGFRa positive cells in the fetal liver or not and PDGFRa signaling in the fetal liver is actually involved in erythropoiesis. To overcome these issues, we cultured fetal liver cells in the presence or absence of PDGFRa positive cells or PDGF-AA and observed the development of erythrocyte progenitors by the analysis of colony forming unit (CFU)-erythrocyte (E) formation (Fig. 5A) .
Results showed that the number of CFU-containing granulocytes (G), macrophage (M), granulocyte/macrophage (GM) slightly increased by the addition of PDGF-AA in the presence of PDGFRa positive cells. Moreover, depletion of PDGFRa positive cells from total fetal liver cells slightly reduced the generation of CFU-G, M, and GM formation. However, in both cases, there are no significant differences statistically (Fig. 5B) . On the other hand, in case of CFU-E formation (Fig. 5C ), the number of CFU-E increased by the addition of PDGF-AA in the presence of PDGFRa positive cells. Moreover, depletion of PDGFRa positive cells from total fetal liver cells dramatically reduced the generation of CFU-E.
Finally, we observed whether or not PDGF-AA or -BB affect the Epo expression in the culture of fetal liver cells. As shown in Fig. 6 , both of PDGF-AA and PDGF-BB induced the Epo expression in fetal liver cells.
Taken together, these indicated that PDGFR signal via PDGFRa positive cells are required for the generation of definitive erythrocytes in the fetal liver.
DISCUSSION
The question addressed in this study was how PDGF is involved in the embryonic erythropoiesis. Studies of mice bearing a null mutation of PDGF-B (7) and its receptor (8) indicated that these signals might be involved in the fetal erythropoiesis, as anemia is a key phenotype of these mutant embryos. In this study, we demonstrated that PDGFRa positive cells in the fetal liver regulate definitive erythropoiesis. Adult type erythrocyte precursors may express PDGFRa that functions in their proliferation. Although several studies support this notion (9, 29) , the results presented here argue against the expression of PDGFRa in hematopoietic cells at any stage of embryogenesis. We showed this by immunohistostaining and by flowcytometry. It is difficult to explain the discrepancy between our results and those of others. As our mAb recognizes the ligand-binding site of PDGFRa, functional PDGFRa molecules should be recognized by our mAb. Thus, the positive signal found in embryonic erythrocytes by other groups may be due to either the nonfunctional, truncated molecule, or non-specific background. Indeed, fetal erythrocytes display higher background upon in situ hybridization.
We then examined which cells express PDGFRa and how PDGFRa positive cells are involved in hematopoiesis. The present results suggested that stromal cells rather than erythrocyte progenitors express PDGFRa. Using a mAb specific to Flk1 that is expressed in the vascular endothelium, we demonstrated that PDGFRa + cells are different from the vascular endothelium. Thus, the effect of PDGF on erythropoietic progenitors should be transferred indirectly to the erythrocyte progenitors via PDGFRa + stromal cells in the microenvironment. However, an anti-PDGFRa antibody injection into adult mice did not suppress the adult erythropoiesis (data not shown). This suggested that the PDGF signal plays an essential role in establishing the microenvironment to initiate adult type erythropoiesis, whereas the established adult intramarrow microenvironment is maintained by different mechanisms.
A phenotype found in the anti-PDGFRa antibody injected mouse was similar with mice that bear a null mutation either of erythropoietin (3) or erythropoietin receptors (3, 4) , as maturation arrest of definitive erythroid progenitor cells and complete lack of mature enucleated erythrocyte are key phenotypes. Though anti-PDGFRa antibody injected mouse had a few enucleated mature erythrocytes, primitive erythrocytes were abundantly observed in E15.5 fetal liver of anti-PDGFRa antibody injected embryo. Moreover, the production of erythropoietin starts in fetal liver at around E13 earlier than in the kidney (30, 31) . This suggests the possibility that PDGFRa provides an important signal for establishing the stromal component that can secrete Epo.
In this context, it is notable that PDGFRa expression in the stromal cell component is found in the fetal liver, but not in the yolk sac. Hence, the first wave of erythropoiesis is independent from the PDGFRa signal and therefore all the erythrocytes produced from yolk sac remain primitive. However, as soon as active hematopoiesis shifts to the fetal liver where the microenvironment is stimulated by PDGF, the shift to adult type erythropoiesis would be facilitated. In this respect, stromal cells in the hematopoietic site can provide a molecular cue to shift to the adult type erythrocytes. In deed, we found that Epo expression is observed in PDGFRa positive cell component but not in PDGFRa negative cell component of E12.5 fetal liver and we found that Epo expression is induced by PDGF-AA or PDGF-BB directly in in vitro culture of fetal liver cells. If the induction of Epo at the site of hematopoiesis is a role of PDGFRa, then the anti-PDGFRa antibody injection would not suppress adult erythropoiesis because the site of Epo production shifts to the kidney in adult (32) .
It has been reported that Epo mRNA in the liver is expressed in the fibroblast-like Ito cells and it in the kidney is expressed in proximal tubular cells (5) . We tried to isolate PDGFRa positive cells from the fetal liver and to culture those cells. However, we could not succeed to culture and maintain the survival of PDGFRa positive cells by means of generally used in vitro culture system. An attempt to isolate PDGFRa + stromal cell components is currently underway in our laboratory to understand the characteristic differences between PDGFRa + cells in the fetal liver and proximal tubular cells in the kidney for the regulation of Epo production. Whether suppression of PDGFRa signal decreases the expression of Epo or affects the CFU-E formation or not is under way using the isolated PDGFRa + cells from fetal liver or such isolated PDGFRa + cells with hematopoietic progenitors from fetal liver.
